I think there was also the issue of market manipulation with the...

First 10 Last

Share
Profile

Follow
shanemmarch

88 Posts.

27/02/18

16:30

Post #: 31386430
Share

Originally posted by PizzaComposer ↑

EVE invested in Meluka Health, on the basis that they had identified an opportunity for an Australian brand to take on New Zealand's Manuka Health. They felt that they where "ahead of the trend" when they chose to invest in Meluka Health.

Key reasons for EVE's investment was to start Australia's first specialty honey brand, and has been all along. The premise is that Australia has a greater reputation than New Zealand, and we're missing out on an opportunity to create a brand to take them on.

This investment validates that specialty honey industry is gaining traction and recognition and validates EVE's decision to invest.

This is why I invested why the price was low. I suspect the reason the price peaked was because of the magic word "HEMP/MJ". I suspect that after the crash, that all the speculative "HEMP/MJ" money has left the SP, and that the majority of leftover holders are those who invested based on building a competing brand with Manuka Health.

I believe there is a Meluka whitepaper coming. If we can get that, to prove that it is scientifically better than Manuka, we can ride the coat tails of Manuka Health's success. DYOR on this statement.

I'm anxious to find out the results of the Expo as well and whether our honey will be well received.

"Oh you like Manuka honey? Well, have you heard of Maluka Honey? It's twice as good, and comes from Organic AUSTRALIAN Honey Bees." - The American and Asian market are going to lap that right up.

Expand

I think there was also the issue of market manipulation with the big spike at the end of last year... But is there any reason we can't see 3c again in a few months if sales are good?

EVE Price at posting: 1.1¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

MM1

Geochemical work at Newington picks up gold and copper anomalies for Midas

BGL

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

PEC

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

TRP

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel